EUVIMEDEUVIMED entdecken
Crossref

Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood

Gebhard Thoma iD, Odile Decoret, Eric Vangrevelinghe, Markus Trunzer, Andrea Decker, Anette Orjuela Leon, Christian Beerli, Sandro Bruno, Alice Hauchard, Guido Paulat, Hans-Guenter Zerwes, Feriel Hacini-Rachinel

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01735 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Gebhard Thoma und 11 weiteren Autor:innen. Beteiligte Einrichtung: Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland. Hauptthemen laut MEDLINE: Janus Kinase Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: Novartis.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

We describe the discovery and characterization of the supersoft topical JAK inhibitor 3(R), which is potent in biochemical and cellular assays as well as in human skin models. In blood, the neutral ester 3(R) is rapidly hydrolyzed (t1/2 ∼ 6 min) to the corresponding charged carboxylic acid 4 exhibiting >30-fold reduced permeability. Consequently, acid 4 does not reach the intracellular JAK kinases and is inactive in cellular assays and in blood. Thus, hydrolysis by blood esterases leads to the rapid deactivation of topically active ester 3(R) at a rate beyond the maximal hepatic clearance.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Janus Kinase InhibitorsHumansSkinEsterasesHydrolysisEsters

Substanzen

Janus Kinase InhibitorsEsterasesEsters

Autor:innen und Institutionen

  • Global Discovery Chemistry, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.
  • PK Sciences, Novartis Institutes for BioMedical Research, 4002 Basel, Switzerland.
  • Chemical and Pharmaceutical Profiling, Global Drug Development, Novartis Pharma AG, 4002 Basel, Switzerland.
  • Immunology Disease Area, Novartis Institutes for Biomedical Research, 4002 Basel, Switzerland.

ORCID-Profile: Gebhard Thoma

Förderung

  • Novartis

Zitieren

APA

Thoma, G., Decoret, O., Vangrevelinghe, E., Trunzer, M., Decker, A., Orjuela Leon, A., Beerli, C., Bruno, S., Hauchard, A., Paulat, G., Zerwes, H. G., & Hacini-Rachinel, F. (2023). Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01735

Vancouver

Thoma G, Decoret O, Vangrevelinghe E, Trunzer M, Decker A, Orjuela Leon A, et al. Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01735

BibTeX
@article{Thoma2023,
  author = {Thoma, Gebhard and Decoret, Odile and Vangrevelinghe, Eric and Trunzer, Markus and Decker, Andrea and Orjuela Leon, Anette and Beerli, Christian and Bruno, Sandro and Hauchard, Alice and Paulat, Guido and Zerwes, Hans-Guenter and Hacini-Rachinel, Feriel},
  title = {Design of a Supersoft Topical JAK Inhibitor, Which Is Effective in Human Skin but Rapidly Deactivated in Blood},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01735}
}
Kostenlos starten →